13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BGB-3111-305

    Acronym: 

    BGB-3111-305

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III, randomised study of Zanubrutinib (BGB-3111) compared with Ibrutinib in patients with relapsed/refractory chronic lymphocytic Leukemia or small lymphocytic Lymphoma.

    Lay Summary

    Sponsor / Cooperative group

    Beigene

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Recruiting